Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Jul;97(3):983–989. doi: 10.1111/j.1476-5381.1989.tb12040.x

Actions of constrictor (NPY and endothelin) and dilator (substance P, CGRP and VIP) peptides on pig splenic and human skeletal muscle arteries: involvement of the endothelium.

J Pernow 1
PMCID: PMC1854591  PMID: 2474355

Abstract

1. The effects of various vasoactive peptides and the involvement of the endothelium in these effects were studied on small human skeletal muscle arteries (SMA) and pig splenic arteries (SA) in vitro. 2. Under control conditions, neuropeptide Y (NPY) caused potent and strong contractions of both arteries. The maximal effect of NPY 500 nM was similar to that of phenylephrine and noradrenaline (10 microns). Endothelin was approximately 10 fold more potent than NPY in contracting SA, and the maximal response to endothelin 50 nM was 130% of that evoked by phenylephrine. 3. After removal of the endothelium (by rubbing the inner surface of the arteries) neither the maximal effect nor the EC50 value of NPY on SMA and SA or those of endothelin on SA were changed from control conditions. 4. The substance P (SP)-induced relaxation of precontracted SMA and SA during control conditions (80-90%) was abolished or greatly reduced after endothelium removal. 5. Under control conditions, calcitonin gene-related peptide (CGRP) was about 10 times more potent than vasoactive intestinal polypeptide (VIP) in relaxing SMA. After endothelium removal the relaxation induced by CGRP on SMA and SA and that of VIP on SMA were not changed from control conditions. 6. It is concluded that, in the SMA and SA, the potent vasoconstrictor effects of NPY and endothelin are mediated by direct actions on the vascular smooth muscle and not via a release of an endothelium-derived contracting factor. Relaxation induced by SP but not that of CGRP and VIP seems to be mediated via the endothelium.

Full text

PDF
983

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brain S. D., Williams T. J., Tippins J. R., Morris H. R., MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. Nature. 1985 Jan 3;313(5997):54–56. doi: 10.1038/313054a0. [DOI] [PubMed] [Google Scholar]
  2. Daly R. N., Hieble J. P. Neuropeptide Y modulates adrenergic neurotransmission by an endothelium dependent mechanism. Eur J Pharmacol. 1987 Jun 26;138(3):445–446. doi: 10.1016/0014-2999(87)90486-9. [DOI] [PubMed] [Google Scholar]
  3. Edvinsson L., Fredholm B. B., Hamel E., Jansen I., Verrecchia C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett. 1985 Jul 31;58(2):213–217. doi: 10.1016/0304-3940(85)90166-1. [DOI] [PubMed] [Google Scholar]
  4. Franco-Cereceda A., Henke H., Lundberg J. M., Petermann J. B., Hökfelt T., Fischer J. A. Calcitonin gene-related peptide (CGRP) in capsaicin-sensitive substance P-immunoreactive sensory neurons in animals and man: distribution and release by capsaicin. Peptides. 1987 Mar-Apr;8(2):399–410. doi: 10.1016/0196-9781(87)90117-3. [DOI] [PubMed] [Google Scholar]
  5. Franco-Cereceda A., Rudehill A., Lundberg J. M. Calcitonin gene-related peptide but not substance P mimics capsaicin-induced coronary vasodilation in the pig. Eur J Pharmacol. 1987 Oct 13;142(2):235–243. doi: 10.1016/0014-2999(87)90112-9. [DOI] [PubMed] [Google Scholar]
  6. Fredholm B. B., Jansen I., Edvinsson L. Neuropeptide Y is a potent inhibitor of cyclic AMP accumulation in feline cerebral blood vessels. Acta Physiol Scand. 1985 Jul;124(3):467–469. doi: 10.1111/j.1748-1716.1985.tb07683.x. [DOI] [PubMed] [Google Scholar]
  7. Furchgott R. F. The role of endothelium in the responses of vascular smooth muscle to drugs. Annu Rev Pharmacol Toxicol. 1984;24:175–197. doi: 10.1146/annurev.pa.24.040184.001135. [DOI] [PubMed] [Google Scholar]
  8. Han C., Abel P. W. Neuropeptide Y potentiates contraction and inhibits relaxation of rabbit coronary arteries. J Cardiovasc Pharmacol. 1987 Jun;9(6):675–681. doi: 10.1097/00005344-198706000-00006. [DOI] [PubMed] [Google Scholar]
  9. Hellström P. M., Olerup O., Tatemoto K. Neuropeptide Y may mediate effects of sympathetic nerve stimulations on colonic motility and blood flow in the cat. Acta Physiol Scand. 1985 Aug;124(4):613–624. doi: 10.1111/j.1748-1716.1985.tb00055.x. [DOI] [PubMed] [Google Scholar]
  10. Högestätt E. D., Andersson K. E., Edvinsson L. Mechanical properties of rat cerebral arteries as studied by a sensitive device for recording of mechanical activity in isolated small blood vessels. Acta Physiol Scand. 1983 Jan;117(1):49–61. doi: 10.1111/j.1748-1716.1983.tb07178.x. [DOI] [PubMed] [Google Scholar]
  11. Lundberg J. M., Rudehill A., Sollevi A., Theodorsson-Norheim E., Hamberger B. Frequency- and reserpine-dependent chemical coding of sympathetic transmission: differential release of noradrenaline and neuropeptide Y from pig spleen. Neurosci Lett. 1986 Jan 2;63(1):96–100. doi: 10.1016/0304-3940(86)90020-0. [DOI] [PubMed] [Google Scholar]
  12. Lundberg J. M., Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand. 1982 Dec;116(4):393–402. doi: 10.1111/j.1748-1716.1982.tb07157.x. [DOI] [PubMed] [Google Scholar]
  13. Luscher T. F., Vanhoutte P. M. Endothelium-dependent responses in human blood vessels. Trends Pharmacol Sci. 1988 May;9(5):181–184. doi: 10.1016/0165-6147(88)90035-1. [DOI] [PubMed] [Google Scholar]
  14. Pernow J., Boutier J. F., Franco-Cereceda A., Lacroix J. S., Matran R., Lundberg J. M. Potent selective vasoconstrictor effects of endothelin in the pig kidney in vivo. Acta Physiol Scand. 1988 Dec;134(4):573–574. doi: 10.1111/j.1748-1716.1998.tb08538.x. [DOI] [PubMed] [Google Scholar]
  15. Pernow J. Co-release and functional interactions of neuropeptide Y and noradrenaline in peripheral sympathetic vascular control. Acta Physiol Scand Suppl. 1988;568:1–56. [PubMed] [Google Scholar]
  16. Pernow J., Kahan T., Hjemdahl P., Lundberg J. M. Possible involvement of neuropeptide Y in sympathetic vascular control of canine skeletal muscle. Acta Physiol Scand. 1988 Jan;132(1):43–50. doi: 10.1111/j.1748-1716.1988.tb08296.x. [DOI] [PubMed] [Google Scholar]
  17. Pernow J., Lundberg J. M., Kaijser L. Vasoconstrictor effects in vivo and plasma disappearance rate of neuropeptide Y in man. Life Sci. 1987 Jan 5;40(1):47–54. doi: 10.1016/0024-3205(87)90251-7. [DOI] [PubMed] [Google Scholar]
  18. Pernow J., Svenberg T., Lundberg J. M. Actions of calcium antagonists on pre- and postjunctional effects of neuropeptide Y on human peripheral blood vessels in vitro. Eur J Pharmacol. 1987 Apr 14;136(2):207–218. doi: 10.1016/0014-2999(87)90712-6. [DOI] [PubMed] [Google Scholar]
  19. Potter E. K. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther. 1988;37(2):251–273. doi: 10.1016/0163-7258(88)90028-9. [DOI] [PubMed] [Google Scholar]
  20. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., Yazaki Y., Goto K., Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988 Mar 31;332(6163):411–415. doi: 10.1038/332411a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES